# PaxMedica (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher

* PaxMedica has received an urgent plea from the Ministry of Health of Malawi for emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region
* PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, transmitted by tsetse flies
* PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide resources to ensure a steady supply of suramin to endemic regions

 PaxMedica (NASDAQ: PXMD), a biopharmaceutical firm dedicated to advancing treatments for neurological disorders, recently announced that it has received an urgent plea from the Ministry of Health (“MOH”) of Malawi. The MOH is requesting emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region (https://ibn.fm/wWNpQ).

 Following the recent completion of its three pivotal registration/validation batches of PAX-101 (an IV form of suramin), PaxMedica has promptly brought this urgent request to the attention of the U.S. Food and Drug Administration (“FDA”). The company aims to assess any potential impact on its ongoing…

 Read More>>

 NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

 Corporate Communications

 IBN (InvestorBrandNetwork)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com 

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ult-prem/paxmedica-nasdaq-pxmd-seeking-to-qualify-for-neglected-tropical-disease-priority-review-voucher/) 

[Newsramp.com TLDR](https://newsramp.com/None) 